Investments in pharmaceutical companies remain challenging due to the inherent uncertainties of risk assessment.
Our paper aims to assess the impact of the drug development setbacks (DDS) on the stock price of pharmaceutical companies while taking into account the company’s financial situation, pipeline size and trend of the stock price before the DDS.
The model-based clustering based on finite Gaussian mixture modeling was employed to identify the clusters of pharmaceutical companies with homogenous parameters. An artificial neural network was constructed to aid the prediction of the positive mean rate of return 120 days after the DDS.
Our results reveal that a higher pipeline size and a lower rate of return before the DDS, as well as a lower ratio of the market value of the equity and the book value of the total liabilities, are associated with a positive mean rate of return 120 days after the DDS.
In general, the DDS have a negative impact on the company’s stock price, but this risk can be minimized by investors choosing the companies that satisfy certain criteria.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Thakor RT, Anaya N, Zhang Y, Vilanilam C, Siah KW, Wong CH, et al. Just how good an investment is the biopharmaceutical sector? Nat Biotechnol. 2017;35:1149–57.
Popa C, Holvoet K, Van Montfort T, Groeneveld F, Simoens S. Risk-return analysis of the biopharmaceutical industry as compared to other industries. Front Pharmacol. 2018;9:1108.
Jekunen A. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets. Drug Des Devel Ther. 2014;8:2009–16.
Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS. Company stock prices before and after public announcements related to oncology drugs. JNCI J Natl Cancer Inst. 2011;103:1507–12.
Hwang TJ. Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS One. 2013;8:e71966.
Agarwal V, Taffler R. Does financial distress risk drive the momentum anomaly? Financ Manag. 2008;37:461–84.
Eisdorfer A, Goyal A, Zhdanov A. Distress anomaly and shareholder risk: international evidence. Financ Manag. 2018;47:553–81.
Sedighi M, Jahangirnia H, Gharakhani M, Farahani Fard S. A novel hybrid model for stock Price forecasting based on metaheuristics and support vector machine. Data. 2019;4:75.
Evaluate Ltd. EvaluatePharma ® 2017 ®. In: EvaluatePharma ® 2017 [Online document] https://www.evaluate.com/products-services/pharma/evaluatepharma, .
Evaluate Ltd. EvaluatePharma ® 2018 ®. In: EvaluatePharma ® 2018 [Online document] https://www.evaluate.com/products-services/pharma/evaluatepharma, .
Jacquier E, Kane A, Marcus AJ. Geometric or arithmetic mean: a reconsideration. Financ Anal J. 2003;59:46–53.
Bessembinder H. Do stocks outperform Treasury bills? J Financ Econ. 2018;129:440–57.
Alaka HA, Oyedele LO, Owolabi HA, Kumar V, Ajayi SO, Akinade OO, et al. Systematic review of bankruptcy prediction models: towards a framework for tool selection. Expert Syst Appl. 2018;94:164–84.
Malsiner-Walli G, Frühwirth-Schnatter S, Grün B. Model-based clustering based on sparse finite Gaussian mixtures. Stat Comput. 2016;26:303–24.
Melnykov V, Maitra R. Finite mixture models and model-based clustering. Stat Surv. 2010;4:80–116.
Scrucca L, Fop M, Murphy TB, Raftery AE. Mclust 5: clustering, classification and density estimation using Gaussian finite mixture models. R J. 2016;8:289–317.
Raudys Š, Jain AK. Small sample size problems in designing artificial neural networks. Mach Intell Pattern Recognit. 1991;11:33–50.
Günther F, Fritsch S neuralnet: Training of Neural Networks.
Beck MW. NeuralNetTools : visualization and analysis tools for neural networks. J Stat Softw. 2018;85:1–20.
Olden JD, Joy MK, Death RG. An accurate comparison of methods for quantifying variable importance in artificial neural networks using simulated data. Ecol Model. 2004;178:389–97.
Di Zio M, Guarnera U, Rocci R. A mixture of mixture models for a classification problem: the unity measure error. Comput Stat Data Anal. 2007;51:2573–85.
Yiu KK, Mak MW, Li CK. Gaussian mixture models and probabilistic decision-based neural networks for pattern classification: a comparative study. Neural Comput & Applic. 1999;8:235–45.
Strand V, Girolomoni G, Schiestl M, Ernst Mayer R, Friccius-Quecke H, McCamish M. The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Curr Med Res Opin. 2017;33:993–1003.
Penman SH, Richardson SA, Tuna İ. The book-to-Price effect in stock returns: accounting for leverage. J Account Res. 2007;45:427–67.
Myers SC. Determinants of corporate borrowing. J Financ Econ. 1977;5:147–75.
Altman EI, Altman, I. E (2018) Applications of distress prediction models: what have we learned after 50 years from the Z-score models? Int J Financ Stud 6:70.
Wu Y, Gaunt C, Gray S. A comparison of alternative bankruptcy prediction models. J Contemp Account Econ. 2010;6:34–45.
Cai J, Zhang Z. Leverage change, debt overhang, and stock prices. J Corp Finan. 2011;17:391–402.
Lin F-L, Chang T. Does debt affect firm value in Taiwan? A panel threshold regression analysis. Appl Econ. 2011;43:117–28.
Frunza M-C, Frunza M-C. Efficient market hypothesis testing. Solving Mod Crime Financ Mark. 2016:303–10.
McKay DR, Peters DA. What’s the difference between a hedge fund and a mutual fund? Plast Surg (Oakville, Ont) 22:270–1. 2014.
Malkiel BG. The efficient market hypothesis and its critics. J Econ Perspect. 2003;17:59–82.
Availability of data and material
available upon request.
R software was used. Script is available upon request.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Silvijus Abramavičius and Alina Stundžienė Shared first authorship
Electronic supplementary material
About this article
Cite this article
Abramavičius, S., Stundžienė, A., Korsakova, L. et al. Stock price reaction to the drug development setbacks in the pharmaceutical industry. DARU J Pharm Sci (2021). https://doi.org/10.1007/s40199-020-00349-6
- Pharmaceutical companies
- Investment risk assessment
- Stock price
- Drug development setbacks